Experimental drug NU-9 - a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) - improves ...

Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves ...

Amyotrophic_Lateral_Sclerosis_Market_ MRFR reveals steady growth in the ALS market, projecting an increase from $0.94 billion in 2023 to $1 ...

A new study reveals that the thalamus, long overshadowed by the cortex and hippocampus, plays a crucial role in shaping and ...

Sea’s pre-clinical stage neurotherapeutic synthetic oral molecules act at the neurotransmitter glutamate pathway on two clinically validated targets in the CNS (central nervous system) ...

AI Innovation Unlocks Non-Surgical Way to Detect Brain Cancer Spread Jan. 14, 2025 — Researchers have developed an artificial intelligence (AI) model to detect the spread of metastatic brain ...

The DAM-Decision and Memory group at Universitat Jaume I in Castelló, led by Raphael Kaplan and composed of researchers from ...

Neurizon Therapeutics Limited (“Neurizon”), a clinical-stage biotech company dedicated to advancing treatments for ...

Neurizon Therapeutics (ASX: NUZ) has announced encouraging outcomes from an independent study assessing its neuroprotective candidate, NUZ-001, using Tessara Therapeutics' 3D human brain model. The ...

Neurizon Therapeutics (ASX: NUZ) has reported positive results from an independent study into the effects of neuroprotective ...